Fig. 6

WSB1 suppressed GSK3β via ubiquitination-mediated degradation of in myocardial cells. A The level of WSB1 in myocardial cells with CHX administration for 0 h, 3 h, 6 h, 9 h, 12 h or15 h and WSB1 overexpression. B The exogenous WSB1 and cellular GSK3β levels in myocardial cells with WSB1 overexpression and application of CHX or/and MG132. C The ubiquitin content bound by GSK3β antibody was determined by co-IP in myocardial cells with/without WSB1 overexpression. D Co-IP was carried out to confirm the combination of exogenous WSB1 and GSK3β in myocardial cells. E The binding between endogenous WSB1 and GSK3β was verified by co-IP in myocardial cells with OGD/R treatment. F The binding of WSB1 to wild type or mutant GSK3β was detected. (G) The wild type or mutant GSK3β level was examined after WSB1 overexpression and CHX administration. (OGD, oxygen-sugar deprivation; WSB1, WD repeat and SOCS box containing 1; GSK3β, glycogen synthase kinase 3 beta; WT, wild type; CHX, cycloheximide)